What bispecific antibody formats does AtaGenix support?

We support multiple formats including IgG-like (e.g., CrossMab), tandem scFv, nanobody-based, and fragment-based constructs (e.g., Dubody), with options for humanization, Fc engineering, and affinity maturation.

How do you ensure monomer purity and low aggregation?

Our SEC-HPLC and orthogonal biophysical assays monitor monomer content (typically ≥95% for development-grade materials) while minimizing early-eluting aggregates and late-eluting fragments through optimized expression and purification workflows.

Can AtaGenix provide functional validation such as ELISA or cell-based assays?

Yes. We offer ELISA binding/titer evaluation, competitive binding, and custom cell-based assays to characterize potency, specificity, and mechanism of action across target pairs.

What deliverables do clients receive for bispecific projects?

Typical deliverables include purified antibody, SEC-HPLC purity report, SDS-PAGE images, ELISA data with EC50, and a summary QC/COA. Extended documentation (e.g., method SOPs) can be provided upon request.

How fast can projects move from design to QC release?

Timelines depend on construct complexity, but recombinant expression, purification, and QC can often be completed within a few weeks. We propose a phased plan after technical scoping.

Bispecific Antibody Development

Dubody bispecific antibody quality control: SDS-PAGE under reduced and non-reduced conditions

Fig. 2: Dubody Bispecific Antibody QC

Interpretation:

SDS-PAGE QC: Clear main band with low by-products under non-reducing conditions; expected fragment bands under reducing conditions.
Integrity: No significant degradation or aggregation, suggesting correct folding and stable construct design.
Conclusion: Suitable for advanced purity and functionality evaluation.

$Dubody SEC-HPLC monomer purity analysis: main peak dominance and low aggregate fraction$

Fig. 3: Dubody SEC-HPLC Monomer Purity Analysis

Interpretation:

Monomer Purity: Sharp, symmetrical main peak with high area ratio indicates high homogeneity.
Aggregates/Fragments: Minimal aggregate and fragment peaks, showing good process control.
Implication: High purity reduces immunogenicity and viscosity risks, ensuring predictable therapeutic performance.

Dubody ELISA titer analysis curve: binding strength, signal-to-noise ratio, linear dynamic range

Fig. 4: Dubody ELISA Titer Analysis

Interpretation:

Titration Curve: Signal decreases proportionally with dilution, confirming stable and reproducible binding.
Titer/EC₅₀: Left-shifted EC₅₀ indicates strong apparent affinity with a wide dynamic range.
Batch Consistency: Overlapping curves demonstrate reliable batch-to-batch performance.

By Method

By Application

Bispecific Antibody Development

Case Study

About Us

Core Technologies

Resource Center